ArticleCell death & disease2026
PLAAT2 suppresses gastric cancer progression by facilitating cMyc ubiquitination and inhibiting MEK/ERK signaling.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gastric cancer (GC) is a significant global public health issue due to its high incidence and limited therapeutic options. This study aimed to explore the role of phospholipase A and acyltransferase 2 (PLAAT2) in GC progression and its molecular mechanisms. A total of 116 pairs of GC and adjacent tissues, along with 116 paraffin-embedded GC tissue sections, were collected from the Cancer Hospital of China Medical University. The expression of PLAAT2 in GC tissues and cells was detected using quantitative reverse transcription-polymerase chain reaction and western blot assays. Its effects on proliferation, migration, invasion, and apoptosis were assessed using functional assays. The impact on mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway and EMT-related proteins was examined through western blot. Immunoprecipitation-mass spectrometry (IP-MS), co-immunoprecipitation (co-IP), and ubiquitination assays were conducted to elucidate the molecular mechanisms of PLAAT2 to identify PLAAT2-interacting proteins, particularly its role in cMyc posttranslational regulation. In vivo xenograft models further validated the tumor-suppressive role of PLAAT2. We identified PLAAT2 as a differentially expressed gene associated with prognosis in the datasets of patients with GC. PLAAT2 was downregulated in GC and correlated with poor prognosis. Functional experiments demonstrated that PLAAT2 inhibited GC cell proliferation, migration, and invasion through the MEK/ERK signaling pathway. IP-MS and co-IP revealed that cMyc and tripartite motif containing 32 (TRIM32) were key PLAAT2-binding partners. PLAAT2 facilitated the recruitment of TRIM32 to promote cMyc ubiquitination and degradation, thereby suppressing the MEK/ERK signaling pathway and reducing oncogenic potential in vitro and in vivo. PLAAT2 functions as a tumor suppressor in GC by recruiting TRIM32 to facilitate cMyc ubiquitination and impair MEK/ERK-driven oncogenic signaling, highlighting the PLAAT2/TRIM32/cMyc axis as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.